RecruitingNCT06503393

SENOVIE France - Therapeutic Mobility and Breast Cancer


Sponsor

Institut de Recherche pour le Developpement

Enrollment

1,000 participants

Start Date

Mar 25, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Background In France, there were 61,214 new cases of breast cancer in France in 2023 with an estimated prevalence in 2017 of 913,089 people. It is thus the most common cancer in women, with an incidence that has been increasing since 1990, due both to changes in screening but more recently to a moderate increase in relation to changes in risk factors. Social inequalities in breast cancer are documented, but there are no data on immigrant women, and there is reason to believe that their trajectories may be different from those of women born in France (characteristics and age of cancer onset, problems of access to care, isolation, etc.). The SENOVIE France project aims to better understand the impact of breast cancer on the life trajectories of women born in France and women born in sub-Saharan Africa. Objectives The SENOVIE France survey aims : * To understand how breast cancer (diagnosis, treatment, and breast reconstruction) impacts women's lives that are already affected by migration in many spheres (i.e., social consequences of breast cancer on spheres like family or occupation/financial situation). * To study the therapeutic itineraries (including self-reconstruction) of immigrant women living with breast cancer in the greater Paris area and understand their social determinants. * To observe how gender can shape women's medical and social outcomes in a migration context. Methodology The SENOVIE France survey is a mixed-methods survey with a quantitative and a qualitative component. The quantitative component consists of a quantitative, retrospective, life-event survey carried out among 1000 women living with breast cancer and followed in three health services in the greater Paris area. Women born in France and sub-Saharan Africa will be surveyed. This survey consists of a CAPI patient questionnaire and a biographical grid paper (for the life-event data collection) administered face-to-face by specially trained interviewers, as well as a medical questionnaire completed by the team of the health services concerned. Statistical analyses adapted to longitudinal data will be used to study women's trajectories. The qualitative component consists of a survey by semi-structured interviews with women living with breast cancer and followed in the greater Paris area. These interviews are the subject of an audio recording and then a pseudonymized transcription. Thematic analyses will be carried out with a comprehensive approach that aims to analyze women's experiences. Perspectives and expected results This survey will provide scientific knowledge on the diagnosis, treatment and experience of breast cancer and its impact on the life trajectories of women born in France and sub-Saharan Africa. These results could thus contribute to the improvement of medical and psychosocial care for women living with breast cancer.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (SENOVIE France) looks at the health journeys of women diagnosed with breast cancer, comparing women originally from sub-Saharan Africa to women born in France, to understand how migration and cultural background may affect cancer treatment experiences and outcomes. **You may be eligible if...** - You are a woman aged 18 or older - You were diagnosed with breast cancer between January 1, 2014 and December 31, 2020 - You receive care at one of the partner hospitals in the study - You were born in a sub-Saharan African country (Group 1) OR born in France (Group 2) **You may NOT be eligible if...** - You do not speak French - You are under 18 years old - Your breast cancer was diagnosed before 2014 or after 2020 Talk to your doctor to see if this trial is right for you.

This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.


Locations(3)

Robert Ballanger Hospital Aulnay-Sous-Bois

Aulnay-sous-Bois, France

Delafontaine Hospital Saint-Denis

Saint-Denis, France

Saint-Louis University Hospital AP-HP

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06503393


Related Trials